Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Cytostatic Therapy | Research

PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis

Authors: Jia Zhao, Simeng Zhang, Xiaoyu Guo, Ce li, Bowen Yang, Xiujuan Qu, Shuo Wang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

The combinations of PD-1 inhibitors with paclitaxel/cisplatinum (PD-1 + TP) and fluoropyrimidine/cisplatinum (PD-1 + FP) both have been shown to improve overall survival (OS) and progression-free survival (PFS) in patients with previously untreated, advanced esophageal squamous cell carcinoma (ESCC). However, there is no consensus on which chemotherapy regimen combined with PD-1 has better efficacy. To deal with this important issue in the first-line treatment of patients with ESCC, a network meta-analysis (NMA) was performed.

Methods

Data were collected from eligible studies searched in Medline, Web of Science, PubMed, the Cochrane Library and Embase. The pooled hazard ratio (HR) for the OS, and PFS, odds ratio (OR) for the objective response rate (ORR) and ≥ 3 grade treatment-related adverse events (≥ 3TRAEs) were estimated to evaluate the efficacy of PD-1 inhibitors combined with TP or FP.

Results

Five RCTs and one retrospective study involving 3685 patients and evaluating four treatments were included in this NMA. Compared to other treatments, PD-1 + TP was better. For the PFS, the HRs for PD-1 + TP compared to PD-1 + FP, TP and FP were 0.59 (0.44, 0.80), 0.56 (0.51, 0.61) and 0.45 (0.37, 0.56) respectively. For the OS, PD-1 + TP was also a better treatment compared to other treatments. The HRs were 0.74 (0.56, 0.96), 0.64 (0.57, 0.71), 0.53 (0.43, 0.67) respectively. For the ORR, there was no significant difference between PD-1 + TP and PD-1 + FP, and the ORs were 1.2 (0.69, 2.11). Compare with TP and FP, PD-1 + TP had an obvious advantage, ORs were 2.5 (2.04, 3.04) and 2.95 (1.91, 4.63). For ≥ 3TRAEs, PD-1 + TP compared to other treatments, ORs were 1.34 (0.74, 2.46) and 1.13 (0.92, 1.38) and 2.23 (1.35, 3.69).

Conclusion

PD-1 + TP significantly improved both PFS and OS compared to PD-1 + FP. Taking into account both efficacy and safety, PD-1 + TP may be a superior first-line treatment option for ESCC.
Appendix
Available only for authorised users
Literature
1.
3.
go back to reference Moehler M, Maderer A, Thuss-Patience PC, Brenner B, Meiler J, Ettrich TJ, et al. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol. 2020;31(2):228–35. https://doi.org/10.1016/j.annonc.2019.10.018. Epub 2019 Dec 16. PMID: 31959339.CrossRefPubMed Moehler M, Maderer A, Thuss-Patience PC, Brenner B, Meiler J, Ettrich TJ, et al. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol. 2020;31(2):228–35. https://​doi.​org/​10.​1016/​j.​annonc.​2019.​10.​018. Epub 2019 Dec 16. PMID: 31959339.CrossRefPubMed
4.
go back to reference Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, et al. ESCORT-1st investigators. Effect of Camrelizumab vs Placebo added to Chemotherapy on Survival and Progression-Free Survival in patients with Advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st Randomized Clinical Trial. JAMA. 2021;326(10):916–25. https://doi.org/10.1001/jama.2021.12836. PMID: 34519801; PMCID: PMC8441593.CrossRefPubMedPubMedCentral Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, et al. ESCORT-1st investigators. Effect of Camrelizumab vs Placebo added to Chemotherapy on Survival and Progression-Free Survival in patients with Advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st Randomized Clinical Trial. JAMA. 2021;326(10):916–25. https://​doi.​org/​10.​1001/​jama.​2021.​12836. PMID: 34519801; PMCID: PMC8441593.CrossRefPubMedPubMedCentral
7.
go back to reference Dröge LH, Karras PJ, Guhlich M, Schirmer MA, Ghadimi M, Rieken S, Conradi LC, Leu M. Preoperative radiochemotherapy in esophageal squamous cell Cancer with 5-Fluorouracil/Cisplatin or Carboplatin/Paclitaxel: treatment practice over a 20-Year period and implications for the Individual Treatment Modalities. Cancers (Basel). 2021;13(8):1834. https://doi.org/10.3390/cancers13081834. PMID: 33921384; PMCID: PMC8068912.CrossRefPubMed Dröge LH, Karras PJ, Guhlich M, Schirmer MA, Ghadimi M, Rieken S, Conradi LC, Leu M. Preoperative radiochemotherapy in esophageal squamous cell Cancer with 5-Fluorouracil/Cisplatin or Carboplatin/Paclitaxel: treatment practice over a 20-Year period and implications for the Individual Treatment Modalities. Cancers (Basel). 2021;13(8):1834. https://​doi.​org/​10.​3390/​cancers13081834. PMID: 33921384; PMCID: PMC8068912.CrossRefPubMed
10.
go back to reference Xu L, Chen X, Wang L, Han J, Wang Q, Liu S, Zhang X, Han C. Paclitaxel combined with platinum (PTX) versus fluorouracil combined with cisplatin (PF) in the treatment of unresectable Esophageal cancer: a systematic review and meta-analysis of the efficacy and toxicity of two different regimens. J Gastrointest Oncol. 2023;14(2):1037–51. https://doi.org/10.21037/jgo-23-33. Epub 2023 Apr 12. PMID: 37201087; PMCID: PMC10186517.CrossRefPubMedPubMedCentral Xu L, Chen X, Wang L, Han J, Wang Q, Liu S, Zhang X, Han C. Paclitaxel combined with platinum (PTX) versus fluorouracil combined with cisplatin (PF) in the treatment of unresectable Esophageal cancer: a systematic review and meta-analysis of the efficacy and toxicity of two different regimens. J Gastrointest Oncol. 2023;14(2):1037–51. https://​doi.​org/​10.​21037/​jgo-23-33. Epub 2023 Apr 12. PMID: 37201087; PMCID: PMC10186517.CrossRefPubMedPubMedCentral
11.
go back to reference Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. KEYNOTE-590 Investigators. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71. https://doi.org/10.1016/S0140-6736(21)01234-4. Erratum. In: Lancet. 2021;398(10314):1874 PMID: 34454674.CrossRefPubMed Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. KEYNOTE-590 Investigators. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71. https://​doi.​org/​10.​1016/​S0140-6736(21)01234-4. Erratum. In: Lancet. 2021;398(10314):1874 PMID: 34454674.CrossRefPubMed
14.
go back to reference Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, ORIENT-15 study group, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377:e068714. https://doi.org/10.1136/bmj-2021-068714. PMID: 35440464; PMCID: PMC9016493.CrossRefPubMedPubMedCentral Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, ORIENT-15 study group, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377:e068714. https://​doi.​org/​10.​1136/​bmj-2021-068714. PMID: 35440464; PMCID: PMC9016493.CrossRefPubMedPubMedCentral
16.
go back to reference Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network metaanalysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–17.CrossRefPubMedPubMedCentral Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network metaanalysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–17.CrossRefPubMedPubMedCentral
17.
go back to reference van Valkenhoef G, Lu G, de Brock B, et al. Automating network meta-analysis. Res Synth Methods. 2012;3(4):285–99.CrossRefPubMed van Valkenhoef G, Lu G, de Brock B, et al. Automating network meta-analysis. Res Synth Methods. 2012;3(4):285–99.CrossRefPubMed
20.
go back to reference Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. National Institute for Health and Care Excellence (NICE); London: 2014. NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. National Institute for Health and Care Excellence (NICE); London: 2014. NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials.
22.
go back to reference Liu Y, Ren Z, Yuan L, Xu S, Yao Z, Qiao L, Li K. Paclitaxel plus Cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell Esophageal cancer. Am J Cancer Res. 2016;6(10):2345–50 PMID: 27822423; PMCID: PMC5088297.PubMedPubMedCentral Liu Y, Ren Z, Yuan L, Xu S, Yao Z, Qiao L, Li K. Paclitaxel plus Cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell Esophageal cancer. Am J Cancer Res. 2016;6(10):2345–50 PMID: 27822423; PMCID: PMC5088297.PubMedPubMedCentral
28.
29.
go back to reference Fong A, Durkin A, Lee H. The potential of combining tubulin-targeting Anticancer therapeutics and Immune Therapy. Int J Mol Sci. 2019;20(3) PMID: 30704031; PMCID: PMC6387102.CrossRefPubMedPubMedCentral Fong A, Durkin A, Lee H. The potential of combining tubulin-targeting Anticancer therapeutics and Immune Therapy. Int J Mol Sci. 2019;20(3) PMID: 30704031; PMCID: PMC6387102.CrossRefPubMedPubMedCentral
30.
go back to reference Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors[J]. Nat Rev Clin Oncol. 2020;17(12):725–41.CrossRefPubMed Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors[J]. Nat Rev Clin Oncol. 2020;17(12):725–41.CrossRefPubMed
31.
go back to reference GARNETT C T, SCHLOM J, HODGE JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res. 2008;14(11):3536–44.CrossRefPubMedPubMedCentral GARNETT C T, SCHLOM J, HODGE JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res. 2008;14(11):3536–44.CrossRefPubMedPubMedCentral
32.
go back to reference Pfannenstiel LW, Lam SS, Emens LA, et al. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice[J]. Cell Immunol. 2010;263(1):79–87.CrossRefPubMedPubMedCentral Pfannenstiel LW, Lam SS, Emens LA, et al. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice[J]. Cell Immunol. 2010;263(1):79–87.CrossRefPubMedPubMedCentral
34.
go back to reference Shang X, Zhao G, Liang F, Zhang C, Zhang W, Liu L, et al. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by Surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001). Ann Transl Med. 2022;10(4):229. https://doi.org/10.21037/atm-22-513. PMID: 35280363; PMCID: PMC8908169.CrossRefPubMedPubMedCentral Shang X, Zhao G, Liang F, Zhang C, Zhang W, Liu L, et al. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by Surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001). Ann Transl Med. 2022;10(4):229. https://​doi.​org/​10.​21037/​atm-22-513. PMID: 35280363; PMCID: PMC8908169.CrossRefPubMedPubMedCentral
Metadata
Title
PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis
Authors
Jia Zhao
Simeng Zhang
Xiaoyu Guo
Ce li
Bowen Yang
Xiujuan Qu
Shuo Wang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11715-3

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine